Photo via Pexels
A team of researchers from Great Ormond Street Hospital and the University of Pittsburgh successfully used bacteriophage therapy to treat a 15-year-old cystic fibrosis patient, Isabelle Baumgardner, suffering from a life-threatening, multi-drug resistant *Mycobacterium abscessus* infection. The patient, who had undergone a lung transplant, was rapidly deteriorating with skin lesions and liver failure unresponsive to conventional antibiotics. Scientists identified a cocktail of three bacteriophages that specifically targeted and killed the resistant bacteria, administered intravenously. Within weeks, the patient's skin lesions began to heal, liver function improved, and the bacterial load significantly decreased, leading to a sustained recovery. This landmark case demonstrates the powerful potential of personalized phage therapy against otherwise untreatable bacterial infections, offering a crucial alternative to dwindling antibiotic options.
Editorial check
How this page is checked
Source trail
nature.com
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It’s Fascinating
This case was a critical turning point because conventional antibiotics had completely failed, leaving the patient with no viable treatment options and a grim prognosis. It profoundly shifted the medical community's perception of phage therapy from a niche, experimental treatment to a serious contender for drug-resistant infections. Within 5-10 years, we could see phage therapy becoming a standard, though personalized, treatment option for patients with persistent, antibiotic-resistant infections, potentially integrated into specialized infectious disease centers. Imagine a highly specific 'smart bomb' deployed against bacterial invaders, leaving healthy cells untouched, rather than a broad-spectrum carpet bombing that harms beneficial bacteria too. Patients with chronic, drug-resistant infections, especially those with conditions like cystic fibrosis or compromised immune systems, stand to benefit most. How can we streamline the discovery and regulatory approval process for these highly individualized phage cocktails to make them more broadly accessible? This success story provides compelling evidence that contradicts decades of skepticism in Western medicine regarding phage therapy, which has been used in Eastern Europe for much longer.
Related
Otter.ai
Otter.ai is an AI meeting assistant developed by Otter.ai, Inc. that records, transcribes, and summarizes spoken conversations in real-time. It leverages…
Scrintal
Scrintal is a visual knowledge canvas and note-taking tool developed by a startup, designed to help users think spatially and connect ideas on an infinite…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.